Company Filing History:
Years Active: 2025
Title: Innovations by Tina Geritz Nielsen in Lymphoma Treatment
Introduction
Tina Geritz Nielsen is an accomplished inventor based in Basel, Switzerland. She has made significant contributions to the field of oncology, particularly in improving treatment outcomes for patients with aggressive non-Hodgkin lymphoma. Her innovative approach focuses on predicting tolerability to treatments, which can greatly enhance patient care.
Latest Patents
Tina holds a patent titled "Predicting tolerability in aggressive non-hodgkin lymphoma." This patent describes systems and methods that improve outcomes for subjects with lymphoma. The technology allows patients to potentially avoid conventional treatments that may lead to adverse effects. By utilizing a machine-learning model, the method generates a score that predicts how well a patient can tolerate a specific treatment. This advancement is crucial in personalizing treatment plans for individuals suffering from lymphoma.
Career Highlights
Tina is currently associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. Her work at Genentech has positioned her as a key player in the research and development of therapies for complex diseases.
Collaborations
Tina collaborates with notable colleagues, including Joseph Nathaniel Paulson and Daniel Jay Schneider. Their combined expertise contributes to the advancement of research in the field of oncology.
Conclusion
Tina Geritz Nielsen's innovative work in predicting treatment tolerability for lymphoma patients exemplifies the impact of technology in medicine. Her contributions are paving the way for more effective and personalized treatment options in oncology.